Publications by authors named "S T Sawchak"
In the 5-week, randomized, double-blind, placebo-controlled EMERGENT-1 (NCT03697252), EMERGENT-2 (NCT04659161), and EMERGENT-3 (NCT04738123) trials, xanomeline and trospium chloride (formerly known as KarXT) significantly improved symptoms of schizophrenia and was generally well tolerated. We pooled data from the EMERGENT trials to further characterize the efficacy of xanomeline/trospium and provide sufficient statistical power to analyze responses in participant subgroups. In pooled analyses, xanomeline/trospium significantly improved Positive and Negative Syndrome Scale (PANSS) total score at week 5 versus placebo (least squares mean difference, -9.
View Article and Find Full Text PDFArticle Synopsis
- There is a critical demand for new antipsychotic medications that are more effective and have fewer side effects; xanomeline, a new muscarinic receptor agonist, shows promise in this area, especially when paired with trospium chloride to minimize side effects.
- The EMERGENT-3 trial tested xanomeline-trospium against a placebo in adults with schizophrenia experiencing acute psychosis, taking place at multiple sites in the US and Ukraine from April to December 2022.
- The study aimed to measure changes in psychiatric symptoms using the Positive and Negative Syndrome Scale (PANSS) and assess safety, with results expected to contribute to new treatment options for schizophrenia.
Article Synopsis
- New treatments for schizophrenia are needed, as current options mostly block dopamine receptors, whereas xanomeline offers a different approach as a muscarinic receptor agonist without this blockade.
- The EMERGENT-2 trial tested KarXT, a combination of xanomeline and trospium, for efficacy and safety in hospitalized patients experiencing acute psychosis, assessing changes in the PANSS score over 5 weeks.
- Participants received varying doses of KarXT or a placebo, with results analyzed to determine the effectiveness of the treatment in improving symptoms compared to the placebo group.
Article Synopsis
- * Conducted over 5 weeks with 182 patients, results indicated that those receiving xanomeline-trospium experienced a significantly greater reduction in schizophrenia symptoms, as measured by the PANSS score, compared to the placebo group.
- * While the combination therapy showed improved effectiveness in several secondary measures, there were still some adverse events, although specific common adverse effects were not detailed in the text.